- CH₣311.46bn
- CH₣337.55bn
- CH₣61.52bn
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey
Roche beats revenue estimates, shares slip as copycats eat into Xolair sales (updated)
Roche third quarter sales slightly beat expectations with growth across divisions
Brief: Roche Q3 Sales Up 7% At Constant Exchange Rates
Swiss stocks - Factors to watch on October 22
Brief: Roche Presents Phase III Data Showing 55% Relapse-Rate Reduction For MS Drug Fenebrutinib
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant
Corrected: TABLE-Swiss trade surplus at CHF 4.35 bln in August (Sept. 17)
Table: Swiss trade surplus at CHF 1.31 bln in September
Hansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Roche puts future German investments 'on hold' (updated)
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion
Brief: Hansoh Pharmaceutical Announces Strategic Collaboration And License Agreement With Roche